Biotech Stocks
Recent market-moving SEC filings and news across biotech companies, ranked by Wiseek's 1–10 importance score.
How Wiseek curates this list
Every item here is a high-importance (score ≥ 7) SEC filing or licensed news event for a biotech company, sourced from SEC EDGAR and licensed news wires and ranked by Wiseek's 1–10 importance score. The underlying source is linked from each article. See our methodology and editorial policy.
Related Healthcare industries
Medical Device StocksPharmaceutical StocksHealth Tech StocksDiagnostics & Research StocksMedical Instrument StocksHealthcare Facility Stocks
See the full Healthcare sector feed.
NewcelX Appoints World-Renowned Diabetes Expert Dr. Camillo Ricordi to Scientific Advisory Board
Hyperion DeFi Finalizes New Employment Agreements for CEO, CFO, and General Counsel
Seer Board Urges Shareholders to Vote 'FOR' Current Nominees, Defends Against Activist Takeover
Seres Therapeutics' SER-155 achieves 80% immunosuppressive-free response in irEC trial
Prime Medicine Wins Key Arbitration, PM647 IP Confirmed; Beam's Claims for Damages Denied
Prime Medicine Wins Arbitration Against Beam Therapeutics, Securing PM647 Rights
60 Degrees Pharma Secures Exclusive Option for Castanospermine in Tick-Borne Diseases
Seres Therapeutics Reports Positive SER-155 Clinical Data for irEC, Bolstering Partnership Efforts
FDA Clears UroGen's Next-Gen Oncolytic Virus UGN-501 for Bladder Cancer Clinical Trials
FDA accepts Arcutis' Zoryve sNDA for infant atopic dermatitis; PDUFA set for Feb 2027
Acurx Pharmaceuticals Sets August 14 for Q2 2026 Earnings Call and Business Update
Chemomab Therapeutics to Merge with Precision Medicine Pioneer Scipher Medicine
Chemomab Therapeutics to Merge with Scipher Medicine in Reverse Acquisition, Valued at $150M Pre-PIPE
Aura Biosciences Appoints New Director, Boosts Board Compensation
BioLineRx Reports Strong Preclinical Synergy for GLIX1 in Ovarian Cancer
Ovid Therapeutics Appoints New CFO Charles Carter Following CBFO Jeffrey Rona's Departure
Controlling Shareholder Richard Griffiths Reduces Stake to 21.7% After $16.3M Sales
FDA Validates Urcosimod Phase 3 Path for Neuropathic Corneal Pain, Eyes Single-Trial Registration
FDA Greenlights OKYO Pharma's Urcosimod for Pivotal Phase 3 Trial in Neuropathic Corneal Pain
Ovid Therapeutics Bolsters Executive Team with New CBO, R&D Advisor, and Key Promotions
BioLineRx's GLIX1 Shows Strong Synergy with PARP Inhibitors in Ovarian Cancer, Plans Trial Expansion
Evogene Forms Joint Initiative with Tel Aviv University to Boost AI-Driven Drug Discovery
Satellos Reports Positive Six-Month Interim Data for SAT-3247 in Adult DMD Patients
SAT-3247 Shows Positive Six-Month Data in DMD Adults, Reducing Muscle Fat and Improving Effort
TuHURA Biosciences Draws Additional $1.9M from Credit Facility
Shareholders to Vote on Replacing Supermajority Voting, Permitting Written Consent
CDT Equity Finalizes $1.46M Convertible Loan with J.J. Astor & Co. Amidst Financial Distress
PMGC Holdings Subsidiary Finalizes Exclusive Worldwide Patent License in Aerospace & Defense
Z Squared Finalizes $300M At-The-Market Offering Agreement
Atlas Venture Funds Continue Significant Stock Distribution in Dyne Therapeutics
Atlas Venture Files Intent to Sell $3.5M in Dyne Therapeutics Stock, Continuing Recent Distribution
RA Capital Management Reaffirms 33% Stake in Climb Bio, Appoints New Board Member
ARS Pharmaceuticals Appoints Donn Casale as CEO, Replaces Richard Lowenthal
Nuvalent Amends Merger Statement with Shareholder Demand Letters and Detailed Financial Forecasts
MacroGenics Completes $122.5M Sale of Manufacturing Business to Bora Pharma
Vanda's VCA-894A Receives FDA Rare Pediatric Designation, Potential for Priority Review Voucher
Vertex to Acquire Crinetics for $10 Billion, Expanding Rare Disease Portfolio
CalciMedica Appoints Key Investor Evgeny Zaytsev to Board
Shareholders to Vote on Massive Increase in Authorized Share Capital
Vor Biopharma Appoints Experienced Pharma CEO David Zaccardelli to Board